MODIFIED PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

eduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control der the Paperworl

Substitute for form 1449B/PTO Complete if Known **Application Number** 09/763,175 INFORMATION DISCLOSURE 05/30/2001 Filing Date STATEMENT BY APPLICANT First Named Inventor Hitoshi KIYOI et al. Date Submitted: January 5, 2005 **Group Art Unit** 1642 **Examiner Name** Susan Ungar (use as many sheets as necessary) 084335-0129 Sheet of **Attorney Docket Number**

•				U.S. PATENT DOCUMENTS		
		U.S. Patent Document			Date of Publication of	Pages, Columns, Lines, Where Relevant
Examiner Initials*	Cite No. ¹	Number	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear
$\alpha \nu$	1 A1	5,635,388		BENNETT et al.	06/03/1997	
7						
						
		-	 			
			 			
						

					DREIGN PATENT DOCUMEN			
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or	Date of Publication of Cited Document	Pages, Columns, Lines, Where Relevant	
		Office ³	Number ⁴	Kind Code ⁵ (if known)	Applicant of Cited Documents	MM-DD-YYYY	Passages or Relevant Figures Appear	T ⁶
								<u> </u>
,								
-					,			
• •								
								7

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No.1 Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue nu publisher, city and/or country where published.		of the nber(s),			
Su	A2	KIYOI et al., "FLT3 in Human Hematologic Malignancies," Leukemia and Lymphoma, Vol. 43, No. 8, 2 Taylor & Francis Ltd., pp. 1541-1547.				
gu	А3	ZHAO et al., "In Vivo Treatment of Mutant FLT3-Transformed Murine Leukemia with a Tyrosine Kinase Inhibitor," Leukemia, Vol. 14, 2000, Macmilan Publishers Ltd., pp. 374-378.				

	, ,			
Examiner Signature	, (pr	Date Considered	9/20/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. See attached Kinds of U.S. Patent Documents. Enter Office that issued the document, by the two-letter code (WIPO)

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

Skind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

Applicant is to place a check mark here if English language Translation is attached.